Mobile Menu Mobile Close

Search

LEARN MORE ABOUT OUR FEARLESS PURSUIT

LATEST NEWS

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Acad...

NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS),

Read More >

GET INVESTOR
INFORMATION

HEAR OUR
STORY

READ OUR
PUBLICATIONS

EXPLORE OUR
PIPELINE

JOIN OUR
TEAM

HEAR OUR
STORY

EXPLORE OUR
PIPELINE

READ OUR
PUBLICATIONS

JOIN OUR
TEAM

GET INVESTOR
INFORMATION

LATEST NEWS

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Acad...

NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS),

Read More >
logo

©2022 TG Therapeutics, Inc. All rights reserved. 

You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

CONTINUE Return to tgtherapeutics.com